Population modelling depicts the mutational burden of NPHS2 (podocin) nephropathy and reveals an undiagnosed adult-onset genetic cohort

Sparsentan Reversibly Decreases Mesangial IgA Deposition in gddY Mice: A Possible Role for Mesangial-Cell -Surface Autoantigen Expression

Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)

PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g/g

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial

Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd

Sparsentan Has Direct Effects on the Glomerular Capillary Wall to Attentuate Increased Permeability After Exposure to Nephrotic Syndrome Plasma